136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Acquired by Toronto Dominion Bank

Toronto Dominion Bank acquired a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 136,723 shares of the biopharmaceutical company's stock, valued at approximately $742,000. Toronto Dominion Bank owned approximately 0.22% of Sage Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. US Bancorp DE raised its stake in Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after acquiring an additional 2,268 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 2,446 shares in the last quarter. Picton Mahoney Asset Management increased its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 3,581 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Sage Therapeutics by 31.2% in the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock valued at $99,000 after buying an additional 4,350 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Sage Therapeutics by 5.3% in the fourth quarter. Invesco Ltd. now owns 92,528 shares of the biopharmaceutical company's stock valued at $502,000 after buying an additional 4,629 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Canaccord Genuity Group lowered their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, February 12th. Wedbush restated a "neutral" rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Scotiabank lowered their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research note on Wednesday, February 12th. Finally, Bank of America initiated coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 target price for the company. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $8.81.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE traded up $0.03 during mid-day trading on Thursday, hitting $6.51. The company's stock had a trading volume of 174,771 shares, compared to its average volume of 1,190,156. The stock has a market cap of $407.35 million, a price-to-earnings ratio of -0.99 and a beta of 0.20. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $13.47. The company's fifty day simple moving average is $7.23 and its 200-day simple moving average is $6.74.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the previous year, the business earned ($1.80) EPS. The firm's revenue was up 78.0% compared to the same quarter last year. On average, sell-side analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.